Biotechnology company Inotrem SA revealed on Tuesday the receipt of the US Food and Drug Administration (FDA) Fast Track designation for the nangibotide development programme for the treatment of septic shock.
According to the company, nangibotide, which Phase IIb has just been cleared by the US FDA, is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function and improve post septic shock survival.
Septic shock is the ultimate complication of sepsis. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. The therapeutic solution has the potential to become the first mechanism-based treatment for septic shock.
The company will commence its planned global multicentric Phase IIb study in septic shock patients later this year to demonstrate efficacy of nangibotide and bring a clinically relevant proof of clinical activity in septic shock patients. The study intends to validate a personalized medicine approach using soluble TREM-1 as potential companion diagnostic test to identify patients likely to benefit from nangibotide.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP